Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.

Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW, Clark JI, Baar J, Sosman J, Weber J, Lathia C, Brunetti J, Cihon F, Schwartz B
Clin Cancer Res. 2007 13 (11): 3312-9

PMID: 17545537 · DOI:10.1158/1078-0432.CCR-06-1341

MeSH Terms (15)

Adult Aged Aged, 80 and over Antineoplastic Agents Dose-Response Relationship, Drug Female Humans Interleukin-2 Kidney Neoplasms Lymphocyte Subsets Male Melanoma Middle Aged Recombinant Proteins Skin Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities: